These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 2487791)
21. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Jiang XT; Tao HQ; Zou SC Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690 [TBL] [Abstract][Full Text] [Related]
22. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Liao WC; Wu MS; Wang HP; Tien YW; Lin JT Pancreas; 2009 May; 38(4):422-6. PubMed ID: 19214136 [TBL] [Abstract][Full Text] [Related]
23. Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer. Wu D; Qian JM; Deng RX; Jiang WJ; Chen YJ; Liu XH; Lu XH Chin J Dig Dis; 2006; 7(2):117-20. PubMed ID: 16643340 [TBL] [Abstract][Full Text] [Related]
24. [Early detection of pancreatic cancer by serum markers]. Nakae Y; Naruse S; Shibata T; Kitagawa M; Kondo T; Hayakawa T; Kuno N; Kurimoto K Rinsho Byori; 1994 Feb; 42(2):139-42. PubMed ID: 7511183 [TBL] [Abstract][Full Text] [Related]
25. [Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors]. Markocka-Maczka K Wiad Lek; 2003; 56(11-12):537-40. PubMed ID: 15058160 [TBL] [Abstract][Full Text] [Related]
26. [Value of serum CA 19-9 determination in the diagnosis of pancreatic carcinoma]. Pei DP Zhonghua Wai Ke Za Zhi; 1990 Oct; 28(10):625-7, 638-9. PubMed ID: 2086060 [TBL] [Abstract][Full Text] [Related]
27. Neopterin--a potential factor for differentiation between pancreatic cancer and chronic pancreatitis. Piecuch J; Rudzki M; Orkisz W; Swietochowska E; Wielkoszyński T; Waniczek D; Arendt J; Sosada K; Zurawiński W; Ładny JR Hepatogastroenterology; 2008; 55(81):258-61. PubMed ID: 18507120 [TBL] [Abstract][Full Text] [Related]
28. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer. Novotný I; Dítĕ P; Dastych M; Záková A; Trna J; Novotná H; Nechutová H Hepatogastroenterology; 2008; 55(85):1475-7. PubMed ID: 18795715 [TBL] [Abstract][Full Text] [Related]
29. Tumour markers in pancreatic cancer. Haglund C; Kuusela P; Roberts PJ Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448 [TBL] [Abstract][Full Text] [Related]
30. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases. Piantino P; Andriulli A; Gindro T; Pecchio F; Masoero G; Cavallini G; Naccarato R; Dobrilla G Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359 [TBL] [Abstract][Full Text] [Related]
31. CEACAM1, a novel serum biomarker for pancreatic cancer. Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843 [TBL] [Abstract][Full Text] [Related]
32. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases]. Czakó L; Takács T; Babarczy E; Dux L; Lonovics J Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648 [TBL] [Abstract][Full Text] [Related]
33. [SC6 antigen for the diagnosis of pancreatic cancer before operation]. Guo XZ; Liu ZF; Ai R Zhonghua Yi Xue Za Zhi; 1993 Jan; 73(1):26-8, 61-2. PubMed ID: 8389232 [TBL] [Abstract][Full Text] [Related]
34. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas]. Chen YF Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun; 11(3):229-31. PubMed ID: 2529993 [TBL] [Abstract][Full Text] [Related]
35. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Marchese R; Muleti A; Pasqualetti P; Bucci B; Stigliano A; Brunetti E; De Angelis M; Mazzoni G; Tocchi A; Brozzetti S Pancreas; 2006 Mar; 32(2):171-7. PubMed ID: 16552337 [TBL] [Abstract][Full Text] [Related]
36. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer]. Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018 [TBL] [Abstract][Full Text] [Related]
37. [Monoclonal antibody SPan-1 in the diagnosis of exocrine pancreatic adenocarcinoma]. Frena A; Mazziotti A; La Guardia G; Martin F Chir Ital; 2000; 52(4):369-77. PubMed ID: 11190527 [TBL] [Abstract][Full Text] [Related]
38. Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses. Wachowiak R; Kaifi J; Schwarzenbach H; Yekebas E; Merkert P; Schurr P; Hansen B; Reichelt U; Strate T; Pantel K; Izbicki JR Diagn Mol Pathol; 2007 Sep; 16(3):174-8. PubMed ID: 17721326 [TBL] [Abstract][Full Text] [Related]